摘要
目的 探讨血清circDUSP16是否可作为预测可切除胃癌(GC)辅助化疗疗效和预后的潜在生物学标志物。方法 收集2017年1月至2021年5月期间在我院接受根治性胃癌切除术的226例GC患者的血清样本。另在我院选择209例健康体检者的血清样本作为对照。采用实时荧光定量PCR(qPCR)法检测血清circDUSP16表达水平。化疗结束6个月内出现复发或转移的患者纳入化疗不敏感组,其余则纳入化疗敏感组。结果 GC组血清circDUSP16水平显著高于健康体检者(P<0.001)。血清circDUSP16用于诊断GC的ROC曲线下面积(AUC)为0.874(95%CI:0.843~0.906)。95例(42.0%)GC患者在化疗结束6个月内复发。化疗不敏感组血清circDUSP16表达水平显著高于化疗敏感组(P<0.001)。血清circDUSP16预测化疗敏感性的AUC为0.898(95%CI:0.854~0.941),在最佳截断值1.870时,特异度和灵敏度分别为89.8%和80.8%。多因素Logistic回归分析显示血清circDUSP16是GC患者化疗敏感性的独立因素(P<0.001)。根据GC患者血清circDUSP16中位值分为低表达组(<1.64)和高表达组(≥1.64)。GC患者基线血清circDUSP16低表达组和高表达组总生存率分别为69.9%和14.2%,低表达组患者中位OS期更长(P<0.001)。多因素Cox风险比例回归模型分析显示血清circDUSP16是GC患者的独立预后因素(P<0.001)。结论 血清circDUSP16高水平与GC辅助化疗耐药及生存预后不良有关,有希望作为GC辅助化疗疗效和不良预后的潜在预测指标。
Objective To investigate whether circDUSP16 can be used as a potential biomarker to predict the efficacy and prognosis of adjuvant chemotherapy for resectable gastric cancer(GC). Methods Serum samples were collected from 226 GC patients who underwent radical gastrectomy in our hospital from January 2017 to May 2021. In addition, the serum samples of 209 healthy people in our hospital were selected as control. The expression level of circDUSP16 in serum was detected by real-time quantitative PCR(qPCR). Patients with recurrence or metastasis within 6 months after the end of chemotherapy were included in the chemotherapy insensitive group, while others were included in the chemotherapy sensitive group. Results Serum circDUSP16 level in GC group was significantly higher than that in non-cancer control group(P<0.001). The area under ROC curve(AUC) of serum circDUSP16 for GC diagnosis was 0.874(95%CI: 0.843-0.906). 95 patients(42.0%) with GC relapsed within 6 months after the end of chemotherapy. The expression level of circDUSP16 in serum of chemotherapy insensitive group was significantly higher than that of chemotherapy sensitive group(P<0.001). The AUC of serum circDUSP16 predicted chemotherapy sensitivity was 0.898(95%CI: 0.854-0.941), and the specificity and sensitivity were 89.8% and 80.8%, respectively, at the optimal cut-off value of 1.870. Multivariate Logistic regression analysis showed that serum circDUSP16 was an independent factor for chemotherapy sensitivity in GC patients(P<0.001). According to the median value of circDUSP16 in serum of GC patients, the patients were divided into low expression group(< 1.64) and high expression group(≥1.64). The overall survival rate of baseline GC patients in the low and high circDUSP16 expression groups was 69.9% and 14.2%, respectively, and the median OS stage was longer in the low expression group(P<0.001). Multivariate Cox proportional regression analysis showed that serum circDUSP16 was an independent prognostic factor for GC patients(P<0.001). Conclusion High serum circDUSP16 expression was associated with drug resistance and poor survival prognosis of GC adjuvant chemotherapy, which is promising as a potential predictor of GC adjuvant chemotherapy efficacy and poor prognosis.
作者
时阳
张路遥
曹婷婷
张建广
金国花
SHI Yang;ZHANG Luyao;CAO Tingting;ZHANG Jianguang;JIN Guohua(Department of Gastroenterology,First Hospital of Jilin University,Changchun 130021,China)
出处
《临床肿瘤学杂志》
CAS
2023年第2期112-119,共8页
Chinese Clinical Oncology
基金
吉林省科技厅自然科学基金资助项目(20200201498JC)。
